How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Semaglutide for managing overweight and obesity

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about semaglutide

Marketing authorisation indication

2.1 Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 mg/kg2 (overweight) in the presence of at least one weight-related comorbidity'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics. An induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, is given, with a maintenance dose of 2.4 mg.

Price

2.3 The list price of semaglutide (Wegovy) 2.4 mg and 1.7 mg is commercial in confidence and cannot be reported here. The list price of semaglutide 0.25 mg, 0.5 mg and 1.0 mg is £73.25 per pack (4 pre-filled pens; excluding VAT; BNF online accessed January 2022).